Literature DB >> 9860475

Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.

M G van Ijken1, E A de Bruijn, G de Boeck, T L ten Hagen, J R van der Sijp, A M Eggermont.   

Abstract

OBJECTIVE: To validate the methodology of isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques and to gain insight into the distribution of tumor necrosis factor-alpha (TNF), melphalan, and mitomycin C (MMC) through the regional and systemic blood compartments when applying these techniques. SUMMARY BACKGROUND DATA: There is no standard treatment for unresectable liver tumors. Clinical results of isolated limb perfusion with high-dose TNF and melphalan for the treatment of melanoma and sarcoma have been promising, and attempts have been made to extrapolate this success to the isolated liver perfusion setting. The magnitude and toxicity of the surgical procedure, however, have limited clinical applicability.
METHODS: Pigs underwent IHHP with TNF, melphalan, and MMC using balloon catheters or served as controls, receiving equivalent dosages of these agents intravenously. After a 20-minute perfusion, a washout procedure was performed for 10 minutes, after which isolation was terminated. Throughout the procedure and afterward, blood samples were obtained from the hepatic and systemic blood compartments and concentrations of perfused agents were determined.
RESULTS: During perfusion, locoregional plasma drug concentrations were 20- to 40-fold higher than systemic concentrations. Compared with systemic concentrations after intravenous administration, regional concentrations during IHHP were up to 10-fold higher. Regional MMC and melphalan levels steadily declined during perfusion, indicating rapid uptake by the liver tissue; minimal systemic concentrations indicated virtually no leakage to the systemic blood compartment. During isolation, concentrations of TNF in the perfusate declined only slightly, indicating limited uptake by the liver tissue; no leakage of TNF to the systemic circulation was observed. After termination of isolation, systemic TNF levels showed only a minor transient elevation, indicating that the washout procedure at the end of the perfusions was fully effective.
CONCLUSIONS: Complete isolation of the hepatic vascular bed can be accomplished when performing IHHP using this balloon catheter technique. Thus, as in extremities, an ideal leakage-free perfusion of the liver can now be performed, and repeated, without major surgery. The effective washout allows the addition of TNF in this setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9860475      PMCID: PMC1191594          DOI: 10.1097/00000658-199812000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  40 in total

1.  Early recognition of hepatocellular carcinoma.

Authors:  K Okuda
Journal:  Hepatology       Date:  1986 Jul-Aug       Impact factor: 17.425

2.  A successful technique of in vivo isolated liver perfusion in pigs.

Authors:  C J van de Velde; B J Kothuis; H W Barenbrug; N Jongejan; R D Runia; L M de Brauw; A Zwaveling
Journal:  J Surg Res       Date:  1986-12       Impact factor: 2.192

3.  Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence.

Authors:  K S Hughes; R Simon; S Songhorabodi; M A Adson; D M Ilstrup; J G Fortner; B J Maclean; J H Foster; J M Daly; D Fitzherbert
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

4.  Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.

Authors:  B A Teicher; J S Lazo; A C Sartorelli
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

5.  A technique for isolation perfusion of the canine liver with survival.

Authors:  J L Skibba; U A Almagro; R E Condon; R J Petroff
Journal:  J Surg Res       Date:  1983-02       Impact factor: 2.192

6.  [Isolated liver perfusion with 5-fluorouracil (5-FU) in the human].

Authors:  K Aigner; H Walther; J C Tonn; M Krahl; A Wenzl; G Merker; K Schwemmle
Journal:  Chirurg       Date:  1982-09       Impact factor: 0.955

7.  Phase I study of recombinant tumor necrosis factor in cancer patients.

Authors:  M Blick; S A Sherwin; M Rosenblum; J Gutterman
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

8.  Primary hepatocellular carcinoma--etiology, pathogenesis, and prevention.

Authors:  W T London
Journal:  Hum Pathol       Date:  1981-12       Impact factor: 3.466

9.  The natural history of hepatocellular carcinoma. A study of 100 untreated cases.

Authors:  N Nagasue; H Yukaya; T Hamada; S Hirose; R Kanashima; K Inokuchi
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

10.  Tumour necrosis factor in man: clinical and biological observations.

Authors:  P Selby; S Hobbs; C Viner; E Jackson; A Jones; D Newell; A H Calvert; T McElwain; K Fearon; J Humphreys
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

View more
  7 in total

1.  Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model.

Authors:  Geert Maleux; Diethard Monbaliu; Chris Verslype; Christophe Casteleyn; Marc Van De Velde; Pieter Cornillie; Yvonne Hoogeveen; Eric Van Cutsem
Journal:  Eur Radiol       Date:  2010-05-22       Impact factor: 5.315

2.  Retrograde-outflow percutaneous isolated hepatic perfusion using cisplatin: A pilot study on pharmacokinetics and feasibility.

Authors:  Satoru Murata; Shiro Onozawa; Takahiko Mine; Tatsuo Ueda; Fumie Sugihara; Daisuke Yasui; Shin-Ichiro Kumita; Mitsuo Satake
Journal:  Eur Radiol       Date:  2014-12-18       Impact factor: 5.315

Review 3.  Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?

Authors:  T Pencavel; R Seth; A Hayes; A Melcher; H Pandha; R Vile; K J Harrington
Journal:  Gene Ther       Date:  2010-05-06       Impact factor: 5.250

4.  True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function.

Authors:  Pierluigi Pilati; Simone Mocellin; Carlo R Rossi; Carlo Ori; Federico Innocente; Romano Scalerta; Mauro Ceccherini; Pier Paolo Da Pian; Donato Nitti; Mario Lise
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

5.  Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion.

Authors:  Cornelis Verhoef; Johannes H W de Wilt; Flavia Brunstein; Andreas W K S Marinelli; Boudewijn van Etten; Maarten Vermaas; Gunther Guetens; Gert de Boeck; Ernst A de Bruijn; Alexander M M Eggermont
Journal:  Ann Surg Oncol       Date:  2008-02-01       Impact factor: 5.344

6.  Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.

Authors:  A L Vahrmeijer; J H van Dierendonck; H J Keizer; J H Beijnen; R A Tollenaar; M E Pijl; A Marinelli; P J Kuppen; J H van Bockel; G J Mulder; C J van de Velde
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

7.  Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors.

Authors:  B van Etten; A M M Eggermont; G Ambagtsheer; S T van Tiel; T L M ten Hagen
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.